Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor
Filed with ASX · · 2 pages · English
Earlier from Syntara
- FDA Factory Approval and Relaunch of Aridol in US Market
- Capital Raising Presentation
- Trading Halt Announcement - System Upgrade
- Quarterly Shareholder Update - June 2018
- LOXL2 Program Attracts Strong Partner Interest at BIO18
Later from Syntara
- Pharmaxis Releases Positive Results of Phase 1 Clinical Tria
- LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready
- Pharmaxis AGM - CEO Presentation
- Pharmaxis Announces First Relaunch Sales of Aridol in USA
- Pharmaxis announces resubmission of bronchitol nda in usa
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara